Biomira Expands Oncology Pipeline With ProlX Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
ProlX's lead agent is scheduled to enter Phase II for pancreatic cancer.
You may also be interested in...
Merck KGaA’s Cyanide Poisoning Agent Cyanokit Approved With Pivotal Animal Data
The product will launch in first quarter 2007, U.S. subsidiary VP-Regulatory Affairs Elliot Berger tells “The Pink Sheet” DAILY.
Merck KGaA’s Cyanide Poisoning Agent Cyanokit Approved With Pivotal Animal Data
The product will launch in first quarter 2007, U.S. subsidiary VP-Regulatory Affairs Elliot Berger tells “The Pink Sheet” DAILY.
Merck KGaA Ends Theratope Cancer Vaccine Co-Development; Biomira Seeks New Partner
Merck decided against pursuing development of the oncologic following a disappointing Phase III trial because additional trials would likely be needed to support a regulatory submission. Biomira says it does not have enough cash to support an additional Phase III program on its own.